Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012:2012:463574.
doi: 10.1100/2012/463574. Epub 2012 Sep 10.

Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses

René Arnouk  1 , Carlos Henrique Suzuki Bellucci, Roberto Benatuil Stull, José de Bessa Jr, Cesar Augusto Malave, Cristiano Mendes Gomes
Affiliations
Randomized Controlled Trial

Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses

René Arnouk et al. ScientificWorldJournal. 2012.

Abstract

Purpose: To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH).

Materials and methods: Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of BoNT-A into the prostate. The International Prostatic Symptom Score (IPSS), maximum flow rate (Q(max)), post-void residual volume (PVR), PSA levels and prostate volume before injection and after 3 and 6 months were evaluated. Adverse events were compared between the groups.

Results: Thirty four patients were evaluated, including 17 in the BoNT-A 100 U group and 17 in the BoNT-A 200 U group. Baseline characteristics were similar in both groups. Both doses produced significant improvements in IPSS, Q(max) and PVR after 3 and 6 months and both doses promoted comparable effects. Prostate volume was affected by 200 U BoNT-A injection only after 6 months of treatment. PSA levels were significantly affected in the 100 U group only after 6 months of treatment. In the 200 U group, PSA levels were significantly decreased after 3 and 6 months. The complication rate was similar in both groups.

Conclusions: Efficacy and safety of both BoNT-A doses are similar for BPH treatment in the short term followup.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean IPSS of 34 patients treated with 100 and 200 U of intraprostatic BoNT-A.
Figure 2
Figure 2
Mean Qmax⁡ of 34 patients treated with 100 and 200 U of intraprostatic BoNT-A.
Figure 3
Figure 3
Mean PVR of 34 patients treated with 100 and 200 U of intraprostatic BoNT-A.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barry MJ, Roehrborn CG. Extracts from “clinical evidence”: benign prostatic hyperplasia. British Medical Journal. 2001;323(7320):1042–1046. - PMC - PubMed
    1. Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. European Urology. 2000;38(1):2–19. - PubMed
    1. Oesterling JE. Benign prostatic hyperplasia—medical and minimally invasive treatment options. The New England Journal of Medicine. 1995;332(2):99–109. - PubMed
    1. de La Rosette JJMCH, Alivizatos G, Madersbacher S, et al. EAU guidelines on Benign Prostatic Hyperplasia (BPH) European Urology. 2001;40(3):256–264. - PubMed
    1. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. The New England Journal of Medicine. 1996;335(8):533–539. - PubMed

Publication types